SHERIDAN, WYOMING – November 8, 2024 – Sanofi, a global biopharmaceutical company, is taking a bold stance in the fight against cancer by launching a comprehensive program designed to support employees impacted by the disease. Recognizing the profound impact cancer can have on individuals and their families, Sanofi's "Cancer & Work: Acting Together" initiative provides a 360° approach to addressing the financial, emotional, social, and professional needs of its colleagues.

"We're creating an environment where everyone is supported to bring their best self to work," says a Sanofi spokesperson. This commitment is evidenced by Sanofi's participation in Publicis' #WorkingWithCancer global pledge, a public declaration to combat cancer and its associated stigmas in the workplace.

SHERIDAN, WYOMING – November 7, 2024 – Abbott, a global healthcare leader, is proud to announce the formation of Team Abbott, a worldwide community of runners united by their passion for health and fitness.  This initiative underscores Abbott's commitment to helping people live their best lives through the power of good health.

The inspiration behind Team Abbott stems from the recognition that marathons, while individual races, are ultimately a team sport. "Ask anyone who has run one and they’ll tell you: Marathons are a team sport," says an Abbott spokesperson. "Literally speaking, no, marathons can’t be relayed by a team of athletes, nor are they won by team organizations. But the process of training to run 26.2 miles, and attaining the health needed to do so, is a team effort."

SHERIDAN, WYOMING – November 7, 2024 – In an era marked by growing health concerns and disparities, Tanzania is taking proactive strides to bolster its healthcare system. Through strategic investment in medical education and capacity building, the nation is fostering a skilled healthcare workforce to address its unique challenges and improve the well-being of its citizens.

A collaborative endeavor between the Tanzanian Ministry of Health, Siemens Healthineers, and Muhimbili National Hospital (MNH) has yielded a specialized training program for medical engineers and radiographers. Over the past two years, this initiative has empowered more than 100 healthcare professionals with advanced skills in operating state-of-the-art imaging equipment.

SHERIDAN, WYOMING – November 7, 2024 – In an effort to combat the largest blood shortage in a generation, Abbott and the Big Ten Conference have joined forces to launch "The We Give Blood Drive," a conference-wide competition aimed at increasing blood donations. This initiative taps into the competitive spirit of Big Ten universities and their fans, encouraging them to give back to their communities while vying for a $1 million prize and a trip to the 2024 Discover Big Ten Football Championship Game.

The competition, which kicked off on September 26th, has already seen tremendous support, with over 8,000 Big Ten fans, students, and alumni donating blood.  

"We knew as a leader in diagnostics and testing we had to do something powerful to draw in donors," said Abbott Chairman and CEO Robert Ford. "What better way to inspire people to donate than tapping into rivalries between Big Ten schools and offering up a friendly competition.”

SHERIDAN, WYOMING – November 7, 2024 – The world of marathon running has expanded with the addition of the TCS Sydney Marathon presented by Asics to the Abbott World Marathon Majors (AWMM). Starting in 2025, Sydney will join the prestigious ranks of Tokyo, Boston, London, Berlin, Chicago, and New York in hosting one of the world's most renowned marathons.

This exciting development not only adds a new race to the AWMM series but also brings the Southern Hemisphere into the fold, offering runners a unique opportunity to compete in a world-class marathon in a stunning location. The inaugural Sydney Marathon as part of the AWMM is scheduled for August 31, 2025, and anticipation is already building.

"We cannot wait to see our community embrace this race and start planning their visits to run the streets of one of the finest cities in the world,” said AWMM CEO Dawna Stone. "Runners, your Sydney star awaits.”

SHERIDAN, WYOMING – November 7, 2024 – Abbott (NYSE: ABT) today announced significant strides in its pulsed field ablation (PFA) solutions within the electrophysiology field. The company has achieved key milestones, including the early completion of enrollment in the VOLT-AF IDE Study for the Volt™ PFA System and the initiation of the FOCALFLEX trial to evaluate the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ (SE), designed for treating paroxysmal atrial fibrillation. These advancements underscore Abbott's commitment to providing innovative solutions for abnormal heart rhythms like atrial fibrillation (AFib).

In addition, Abbott has received U.S. Food and Drug Administration (FDA) clearance for the Advisor™ HD Grid X Mapping Catheter, Sensor Enabled™, further enhancing cardiac mapping capabilities for both PFA and radiofrequency (RF) ablation procedures.

SHERIDAN, WYOMING – November 7, 2024 – GE HealthCare, a leading global medical technology and diagnostics company, is poised to announce its latest quarterly earnings before the market opens on Wednesday. Financial analysts are predicting an increase in both revenue and profits compared to the same period last year, signaling continued resilience amidst a challenging global economic landscape.

This positive outlook follows a cautious adjustment made by the company in the previous quarter. Citing economic difficulties in China, GE HealthCare revised its full-year revenue growth projections downwards. However, the anticipated strong performance in the current quarter suggests that the company is effectively navigating these challenges and capitalizing on growth opportunities in other markets.

SHERIDAN, WYOMING – November 7, 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) has opened its new Pharma Research and Early Development Center (pRED) at its global headquarters in Basel. The center has 1,800 laboratory and office workplaces, bringing together researchers from different disciplines, explains Roche in a statement. The center’s inauguration was attended by Federal Councillor Guy Parmelin, Head of the Federal Department of Economic Affairs, Education and Research.

“The new pRED Center will play an integral role in collaborating with our research centers across the globe, aiming to boost the effectiveness and efficiency of our R&D, and to deliver the greatest impact for patients,” Thomas Schinecker, CEO of the Roche Group, is quoted as saying.

Further investments in the billions to follow

SHERIDAN, WYOMING – November 7, 2024 – Roche, a global pioneer in pharmaceuticals and diagnostics, is set to present a robust body of data at the upcoming 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego.  With more than 40 abstracts spanning nine blood disorders, Roche's presence at ASH underscores its unwavering dedication to improving outcomes for individuals battling lymphoma.

The company will unveil significant findings from studies evaluating its innovative lymphoma treatments, including Polivy® (polatuzumab vedotin), Lunsumio® (mosunetuzumab), and Columvi® (glofitamab), along with exciting new investigational combination data.

Key Highlights from Roche's ASH 2024 Presentations:

SHERIDAN, WYOMING – November 7, 2024 – Roche, a global healthcare pioneer, has announced continued strong sales growth in the third quarter of 2024. The company's performance was driven by high demand for both its Pharmaceuticals and Diagnostics divisions, with Group sales increasing by 9% at constant exchange rates (CER). [cite: 1, 2, 3]

“Our strong growth momentum continued in the third quarter, reflecting the high demand for our innovative medicines and diagnostic solutions and their positive impact on patients’ lives around the world,” said Roche CEO Thomas Schinecker.

Pharmaceuticals Division

The Pharmaceuticals Division posted sales growth of 7% in the first nine months of 2024, with the base business (excluding COVID-19 products) growing by 9%. [cite: 3, 4, 5] This strong performance was fueled by continued high demand for newer medicines, including Vabysmo (serious eye diseases), Phesgo (breast cancer), and Ocrevus (multiple sclerosis).